Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis

• Published in: European journal of haematology 2023-10, Vol.111 (4), p.536-543
• Main Authors: D'Souza, Anita, Szabo, Aniko, Akinola, Idayat, Finkel, Muriel, Flynn, Kathryn E
• Format: Article
• Language: English
• Subjects: Amyloidosis; Coronary artery disease; Emotions; Fatigue; Fatigue - diagnosis; Fatigue - etiology; Heart diseases; Humans; Immunoglobulin Light-chain Amyloidosis - diagnosis; Immunoglobulin Light-chain Amyloidosis - therapy; Kidneys; Pain; Patient Acuity; Patient Reported Outcome Measures; Sleep
• ISSN: 0902-4441; 1600-0609; 1600-0609
• DOI: 10.1111/ejh.14036

To assess the impact of organ involvement on patient-reported outcomes (PROs) in light chain (AL) amyloidosis. PROs were evaluated using the KCCQ-12, PROMIS-29 + 2, and SF-36 in individuals with AL amyloidosis. The 2004 Mayo system was used to stage disease and cardiac, neurologic, and renal involvement was considered. Global physical and mental health (MH) scores, physical function (PF), fatigue, social function (SF), pain, sleep, and MH domains were evaluated. Effect sizes between scores were measured using Cohen's d. Of 297 respondents, the median age at diagnosis was 60 years with 58% cardiac, 58% renal, and 30% neurologic involvement. Fatigue, PF, SF, and global physical health with PROMIS and SF-36 discriminated the most by stage. Significant discrimination in PROMIS and/or SF-36 was seen in PF, fatigue, and global physical health with cardiac involvement. For neurologic involvement, PF, fatigue, SF, pain, sleep, global physical, and MH with PROMIS and role physical, vitality, pain, general health, and physical component summary with SF-36 were discriminatory. For renal amyloid, pain by SF-36 and PROMIS, and SF-36 MH and role emotional subscales were significant. Fatigue, PF, SF, and global physical health can discriminate stage, cardiac and neurologic, but not renal, AL amyloidosis involvement.